Anle138b

Key Product Details

Product Description

Anle138b is an oligomeric aggregation inhibitor that inhibits formation of pathological prion protein (PrP^Sc) and α-synuclein aggregates in vitro. Anle138b prevents accumulation of PrP^Sc in brain and spleen, and prolongs survival of prion-infected mice. Anle138b exhibits neuroprotective effects in a Parkinson's disease mouse model and improves motor performance in an α-synucleinopathy model. Orally bioavailable and brain penetrant.

Product Specifications for Anle138b

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Anle138b

The following data is based on the product molecular weight 343.18.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.5 mM	5.83 mL	29.14 mL	58.28 mL
2.5 mM	1.17 mL	5.83 mL	11.66 mL
5 mM	0.58 mL	2.91 mL	5.83 mL
25 mM	0.12 mL	0.58 mL	1.17 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Wagner Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease. Acta Neuropathol. 2013 PMID: 23604588

Product Documents for Anle138b